NewAmsterdam Pharma Sees Surge in Trading Volume

Analysts debate whether investors should buy the stock amid mixed ratings.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) saw a 14% increase in trading volume on Monday compared to the previous session, with approximately 802,951 shares traded. The stock last traded at $33.94 after closing at $35.46 the previous day. Analysts have provided a range of ratings on the stock, from 'sell' to 'outperform', with an average 'Moderate Buy' rating and a $47.10 target price.

Why it matters

NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on developing treatments for cardiometabolic diseases. The surge in trading volume suggests increased investor interest, but the mixed analyst ratings indicate uncertainty around the company's prospects.

The details

The trading volume increase came as Wall Street Zen downgraded the stock from 'hold' to 'sell', while Weiss Ratings maintained a 'sell (d-)' rating. On the other hand, Leerink Partners and Guggenheim both have 'outperform' ratings on the stock, with Guggenheim raising its price target from $41 to $45.

  • The trading volume surge occurred on Monday, March 4, 2026.

The players

NewAmsterdam Pharma Company N.V.

A clinical-stage biopharmaceutical company focused on developing treatments for cardiometabolic diseases.

Wall Street Zen

A research firm that downgraded NewAmsterdam Pharma's stock from 'hold' to 'sell'.

Weiss Ratings

A research firm that maintained a 'sell (d-)' rating on NewAmsterdam Pharma's stock.

Leerink Partners

A research firm that has an 'outperform' rating and $55 price target on NewAmsterdam Pharma's stock.

Guggenheim

A research firm that raised its price target on NewAmsterdam Pharma's stock from $41 to $45 and maintained an 'outperform' rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

The mixed analyst ratings and surge in trading volume for NewAmsterdam Pharma suggest investors should closely monitor the company's progress and developments, as the stock's future performance remains uncertain.